JSM 2005 - Toronto

Abstract #304881

This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.



The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

The Program has labeled the meeting rooms with "letters" preceding the name of the room, designating in which facility the room is located:

Minneapolis Convention Center = “MCC” Hilton Minneapolis Hotel = “H” Hyatt Regency Minneapolis = “HY”

Back to main JSM 2005 Program page
Legend: = Applied Session, = Theme Session, = Presenter
Activity Number: 371
Type: Other
Date/Time: Wednesday, August 10, 2005 : 10:30 AM to 12:20 PM
Sponsor: ASA
Abstract - #304881
Title: A Metaanalysis of Effects of COX-2 Inhibitors
Author(s): Patricia Kearney*+
Companies: University of Oxford
Address: Harkness Building, Radcliffe Infirmary, Oxford, OX2 6HE, United Kingdom
Keywords:
Abstract:

We conducted a tabular data metaanalysis of all randomized trials involving coxib versus placebo or coxib versus a traditional NSAID identified from MEDLINE (January 1966--April 2005) and company databases. Individual trialists and companies provided information on the number of patients randomized, number of vascular events, and the time of followup for each randomized group. Overall, in placebo comparisons, allocation to a coxib was associated with an increased risk of a vascular event. This excess risk of vascular events derived primarily from an increased risk of myocardial infarction. In comparisons of coxib versus traditional NSAIDs other than naproxen, there was no significant difference in the risk of vascular events. High-dose naproxen was associated with a lower risk of vascular events than coxibs and, indirectly, than other traditional NSAIDs. To summarize, coxibs increase the risk of vascular events, approximately doubling the risk of myocardial infarction, but NSAIDs are associated with similar hazards. High-dose naproxen is associated with a lower risk of vascular events than other NSAIDs.

  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2005 program

JSM 2005 For information, contact jsm@amstat.org or phone (888) 231-3473. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2005